Why the study?
Familiarity with the features and PET/CT uptake of lipomatous hypertrophy of the interatrial septum is needed to avoid misinterpretation for metastatic disease.
LHIS can exhibit increased 18F-PSMA and 18F-FDG uptake on PET/CT, which should be recognized as a benign anomaly rather than metastatic disease.
PSMA uptake in LHIS may mimic pathology on PET; extends FDG observations and leaves open questions of tracer specificity.
Lipomatous hypertrophy of the interatrial septum (LHIS) is a benign anomaly with low prevalence. Lipomatous hypertrophy of the interatrial septum is asymptomatic in most of the cases and rarely leads to atrial arrhythmias, obstructive flow symptoms, or sudden death. It is mostly diagnosed as an incidental finding in cross-sectional imaging and echocardiography, and increased 18F-FDG uptake on LHIS has been described. We present a case of repeated increased 18F-PSMA uptake in LHIS. Although very rare, familiarity with the typical features and prevalence of LHIS in PET/CT can avoid misinterpretation for metastatic disease.
No takes yet. Share an insight, caveat, or question.
Grünig et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: